Temoside contains temozolomide, an oral chemotherapy medication classified as an alkylating agent. It is primarily used in the treatment of certain brain cancers, including glioblastoma multiforme and anaplastic astrocytoma. Temozolomide has become a key part of standard treatment regimens for these tumors, often used alongside radiotherapy or in follow-up cycles. Its oral administration offers convenience compared to traditional intravenous chemotherapy.

Mechanism of Action
Temozolomide works by damaging the DNA of cancer cells, which prevents them from growing and dividing. Once inside the body, it is converted into a compound that adds methyl groups to the DNA of tumor cells. This damage triggers cell cycle arrest and eventually leads to cell death. Because cancer cells divide more rapidly than normal cells, they are more susceptible to this effect, making temozolomide an effective targeted therapy.

Uses
Temoside is mainly used in the treatment of malignant brain tumors. It is indicated for newly diagnosed glioblastoma multiforme in combination with radiation therapy, followed by maintenance treatment. It is also used in patients with recurrent or progressive anaplastic astrocytoma. In certain cases, it may be considered for other brain tumors or off-label indications based on clinical judgment.

Adverse Effects
Common side effects of temozolomide include nausea, vomiting, fatigue, and loss of appetite. Some patients may experience constipation, headache, or low blood counts, which can increase the risk of infections or bleeding. Less commonly, it can cause liver function abnormalities or allergic reactions. Patients receiving long-term or high-dose therapy should be closely monitored with regular blood tests to ensure safety and adjust treatment as needed.